{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:24:19Z","timestamp":1788531859167,"version":"build-2803163510"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Despite advancements in perioperative and consolidative immunotherapy in early-stage to locally advanced non-small cell lung cancer (NSCLC), recurrence rates remain substantial. In this context, liquid biopsy has transformed the oncological landscape by enabling the non-invasive detection of tumor-derived components, including DNA, cells, and proteins, from biological fluids. Although plasma-based circulating tumor DNA (ctDNA) analysis is routinely used in metastatic NSCLC to identify actionable genomic alterations at diagnosis and mechanisms of acquired resistance to targeted therapies, its application in non-metastatic disease represents a pivotal challenge. Leveraging minimal residual disease (MRD) detection through ctDNA offers the potential for early risk stratification, enabling the identification of patients who may benefit from treatment escalation, such as intensified adjuvant or consolidative regimens, while sparing low-risk patients from unnecessary toxicity through de-escalation strategies. This review summarizes the biological and technological foundations underlying ctDNA-based MRD detection, including tumor-informed and non-tumor-informed approaches, and examines the current evidence supporting its clinical utility in non-metastatic NSCLC. We also highlight key technical and clinical challenges and discuss future perspectives to optimize integration of ctDNA MRD assessment into routine clinical practice.<\/jats:p>","DOI":"10.3389\/fonc.2026.1951454","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:51:29Z","timestamp":1788529889000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["ctDNA-based detection of residual disease: implications for management of non-metastatic NSCLC"],"prefix":"10.3389","volume":"16","author":[{"given":"Charline","family":"Leclercq","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Centre L\u00e9on B\u00e9rard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myl\u00e8ne","family":"Wespiser","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre L\u00e9on B\u00e9rard","place":["Lyon, France"]},{"name":"Univ Lyon, Claude Bernard Lyon 1 University, Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM) 1052, Centre national de la recherche scientifique (CNRS) 5286, Centre L\u00e9on B\u00e9rard, Cancer Research Center of Lyon","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Tachon","sequence":"additional","affiliation":[{"name":"Department of Biopathology, Centre L\u00e9on B\u00e9rard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Buisson","sequence":"additional","affiliation":[{"name":"Department of Biopathology, Centre L\u00e9on B\u00e9rard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice","family":"P\u00e9rol","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre L\u00e9on B\u00e9rard","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Swalduz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Centre L\u00e9on B\u00e9rard","place":["Lyon, France"]},{"name":"Univ Lyon, Claude Bernard Lyon 1 University, Institut national de la sant\u00e9 et de la recherche m\u00e9dicale (INSERM) 1052, Centre national de la recherche scientifique (CNRS) 5286, Centre L\u00e9on B\u00e9rard, Cancer Research Center of Lyon","place":["Lyon, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: A consensus statement from the International Association for the Study of Lung Cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB\u2013IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01681","article-title":"Five-year survival outcomes with atezolizumab after chemotherapy in resected stage IB-IIIA non\u2013small cell lung cancer (IMpower010): An open-label, randomized, phase III trial","volume":"43","author":"Felip","year":"2025","journal-title":"JCO"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non\u2013small-cell lung cancer: Updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"JCO"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK -positive non\u2013small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2602628","article-title":"Selpercatinib in early-stage RET fusion\u2013positive non\u2013small-cell lung cancer","volume":"395","author":"Wu","year":"2026","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR -mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2024.1611817","article-title":"Advancing neoadjuvant therapies in resectable non-small cell lung cancer: Implications for novel treatment strategies and biomarker discovery","volume":"30","author":"Jeon","year":"2024","journal-title":"Pathol Oncol Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1001\/jamaoncol.2022.4457","article-title":"Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: A narrative review","volume":"8","author":"Krebs","year":"2022","journal-title":"JAMA Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113112","article-title":"Implementing ctDNA analysis in the clinic: Challenges and opportunities in non-small cell lung cancer","volume":"12","author":"Gobbini","year":"2020","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s12672-026-04495-2","article-title":"Circulating tumor DNA dynamics predict pathological response and guide therapy personalization in the neoadjuvant setting","volume":"17","author":"Ahmed","year":"2026","journal-title":"Discov Onc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2015.1110021","article-title":"Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: Are we there yet","volume":"15","author":"Polivka","year":"2015","journal-title":"Expert Rev Mol Diagn"},{"key":"B17","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41698-025-00984-9","article-title":"A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer","volume":"9","author":"Boukouris","year":"2025","journal-title":"NPJ Precis Onc"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01929","article-title":"Circulating tumor DNA minimal residual disease detection of non\u2013small-cell lung cancer treated with curative intent","volume":"40","author":"Pellini","year":"2022","journal-title":"JCO"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"12003","DOI":"10.1200\/JCO.2018.36.15_suppl.12003","article-title":"Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: Exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study","volume":"36","author":"Swanton","year":"2018","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35263","article-title":"Detection of circulating tumor DNA with ultradeep sequencing of plasma cell\u2010free DNA for monitoring minimal residual disease and early detection of recurrence in early\u2010stage lung cancer","volume":"130","author":"Tan","year":"2024","journal-title":"Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100106","article-title":"1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)","volume":"16","author":"Felip","year":"2022","journal-title":"Immuno-Oncology Technol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8078","DOI":"10.1200\/JCO.2024.42.16_suppl.8078","article-title":"Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC)","volume":"42","author":"Isbell","year":"2024","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring","volume":"26","author":"Zviran","year":"2020","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"407","DOI":"10.18632\/oncotarget.28581","article-title":"Correction: Analytical validation of NeXT Personal\u00ae, an ultra-sensitive personalized circulating tumor DNA assay","volume":"15","author":"Northcott","year":"2024","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7083","DOI":"10.1016\/j.cell.2025.10.020","article-title":"Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction","volume":"188","author":"Black","year":"2025","journal-title":"Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.12.007","article-title":"Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST)","volume":"35","author":"Gouda","year":"2024","journal-title":"Ann Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41571-024-00967-y","article-title":"Minimal residual disease as a target for liquid biopsy in patients with solid tumours","volume":"22","author":"Pantel","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.06.001","article-title":"Fragmentomic analysis of circulating tumor DNA-targeted cancer panels","volume":"34","author":"Helzer","year":"2023","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S322242","article-title":"Minimal residual disease monitoring in radically treated non-small cell lung cancer: Challenges and future directions","volume":"16","author":"O\u2019Sullivan","year":"2023","journal-title":"OTT"},{"key":"B32","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis Onc"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.766","article-title":"Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: Advances and challenges","volume":"5","author":"Li","year":"2024","journal-title":"MedComm"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/PO-25-00489","article-title":"Predictive effectiveness of circulating tumor DNA in recurrent early-stage non\u2013small cell lung cancer: An updated meta-analysis","volume":"9","author":"Lu","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"104090","DOI":"10.1016\/j.jtho.2026.104090","article-title":"Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer","author":"Cui","year":"2026","journal-title":"J Thorac Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13267","article-title":"Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II\u2013IIIA NSCLC patients","volume":"16","author":"Vessies","year":"2022","journal-title":"Mol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1213","article-title":"Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC)","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1486","article-title":"Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer","volume":"12","author":"Zhang","year":"2022","journal-title":"Cancer Discov"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.055","article-title":"LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial","volume":"34","author":"Reck","year":"2023","journal-title":"Ann Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2025.43.16_suppl.8009","article-title":"Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial","volume":"43","author":"Reck","year":"2025","journal-title":"JCO"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41586-026-10925-6","article-title":"Biomarkers of nivolumab benefit in resectable non-small cell lung cancer","author":"Cascone","year":"2026","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03577-y","article-title":"Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB\u2013IIIA non-small-cell lung cancer","volume":"31","author":"Herbst","year":"2025","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.032","article-title":"OA02.02 Molecular residual disease (MRD) analysis from NeoADAURA: Neoadjuvant osimertinib \u00b1 chemotherapy in resectable EGFRm NSCLC","volume":"20","author":"Blakely","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2443","article-title":"1817MO Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC","volume":"36","author":"Aperribay","year":"2025","journal-title":"Ann Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01828","article-title":"Adjuvant durvalumab in completely resected early-stage non\u2013small cell lung cancer","volume":"44","author":"Goss","year":"2026","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2026.8992","article-title":"Adjuvant nivolumab vs observation in resected non\u2013small cell lung cancer: A randomized clinical trial","volume":"336","author":"Chaft","year":"2026","journal-title":"JAMA"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108635","article-title":"ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC","volume":"206","author":"Schmid","year":"2025","journal-title":"Lung Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"B54","unstructured":"clinicaltrials.gov\n          Effectiveness and safety of dynamic MRD guiding treatment after aumolertinib induction therapy of EGFR-mutation-positive unresectable stage III non-small cell lung cancer in the MDT diagnostic model: An open-label, multicenter, randomized, phase III study\n          \n          2026"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.010","article-title":"Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in NSCLC","volume":"19","author":"Hines","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B56","unstructured":"ClinicalTrials.gov\n          Study details | NCT07120698 | Adaptive adjuvant sintilimab therapy guided by MRD (ADAPT lung)"},{"key":"B57","unstructured":"Yu\n              Q\n            \n          \n          clinicaltrials.gov\n          Minimal residual disease (MRD)-guided adjuvant tislelizumab and chemotherapy in resected stage IIA-IIIB non-small cell lung cancer (NSCLC): A randomized controlled phase II study (Seagull)\n          \n          2023"},{"key":"B58","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12916-023-02954-z","article-title":"Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer","volume":"21","author":"Chen","year":"2023","journal-title":"BMC Med"},{"key":"B59","unstructured":"North Thames Genomic Medicine Service Alliance\n          A health economics evaluation of ctDNA testing in NSCLC\n          \n          2024"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04030-w","article-title":"Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: The randomized phase 2\/3 DYNAMIC-III trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.12.018","article-title":"ctDNA-guided immunotherapy following radical cystectomy for muscle-invasive bladder cancer: Results from the TOMBOLA trial","volume":"37","author":"Dyrskj\u00f8t","year":"2026","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-019-0011-0","article-title":"Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer","volume":"1","author":"Moding","year":"2020","journal-title":"Nat Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1951454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:51:30Z","timestamp":1788529890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1951454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":63,"alternative-id":["10.3389\/fonc.2026.1951454"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1951454","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1951454"}}